Clinical Trial

Innovative Steroid Treatment to Reduce Asthma Development in Children After First-time Rhinovirus Induced Wheezing

Study acronym: INSTAR
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The overall objective of the study is to determine the efficacy of corticosteroids in preventing recurrent wheezing and asthma in high-risk, first-time severe wheezing children with rhinovirus infection, stratified by rhinovirus genome load. The secondary objectives are to determine duration and severity of each acute episode with acute expiratory breathing difficulty, the number of episodes with acute expiratory breathing difficulty, degree of pulmonary hyperreactivity and quality of life within 24 months after study entry.
Protocol Amendment History 12 amendments
This ClinicalTrials.gov record has been amended 12 times since 2019-03-23; most recent amendment 2026-07-16.
Status change: Not Yet Recruiting → Recruiting 2019-07-17
Trial Details
NCT Number NCT03889743
Lead Sponsor St. Olavs Hospital
Collaborators: Turku University Hospital, Karolinska University Hospital, Haukeland University Hospital, University Hospital, Akershus, Helse Stavanger HF, University Hospital of North Norway, Ullevaal University Hospital
Conditions Asthma, Inflammation
Enrollment 280 participants
Start Date 2019-05-08
Primary Completion 2028-05 (estimated)
Study Completion 2028-05 (estimated)
Updated on ClinicalTrials.gov 2026-07-20